Amneal Pharmaceuticals is seeing a significant rise in its stock price after receiving a key FDA approval.
Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) is up 6.20% today, closing at CA$19.87. This increase follows the recent announcement of FDA approval for its lanreotide injection, marking an important milestone for the company.
Advertisement
Amneal Pharmaceuticals, Inc. Class A Common Stock
AMRX.US
AMRX.US
Amneal Pharmaceuticals, Inc. Class A Common Stock
WealthAwesomeMarket cap
$6.30B
P/E
34.8x
52W high
$19.26
52W low
$9.49
1W change
+4.81%
Beta
1.24
Analyst Price Targets
Based on 4 analysts covering AMRX · as of Sep 17, 2026
Wall Street analysts forecast AMRX stock price to rise 18.0% over the next 12 months.
Consensus
Buy4.25 / 5.00
Avg. Target
C$21.33
+18.0% Upside
Current Price
C$18.08
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMRX's historical volatility
30-Day Vol
40.4%
Annualized
90-Day Vol
36.1%
Annualized
Trend (90d)
+33.6%
Annualized drift
90d Mean
C$21.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$19.47 | C$16.94 – C$22.39 |
| 60 trading days | C$20.27 | C$16.64 – C$24.69 |
| 90 trading days | C$21.10 | C$16.57 – C$26.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are reacting positively to Amneal's latest FDA approval, which could boost the company's revenue potential and strengthen its position in the oncology market.
6.20% Gain in Stock Price
Amneal's stock has jumped 6.20% today, reflecting strong investor sentiment following the FDA approval.
Bull case
The FDA approval of the lanreotide injection opens new revenue opportunities for Amneal, potentially increasing its market share in the oncology treatment space, which is valued at nearly $1 billion annually.
Bear case
Despite the good news, analysts warn that Amneal's projected revenue growth is slowing, which could limit the stock's upside potential in the long run.
Advertisement
FDA Approval Boosts Stock
The recent FDA approval for Amneal's lanreotide injection is a significant achievement. This long-acting oncology treatment is expected to enhance the company's Affordable Medicines segment, providing a crucial growth driver. With U.S. annual sales for SOMATULINE® Depot reaching about $983 million, the market potential is substantial.
Market Reaction and Future Outlook
After the announcement, Amneal's stock saw a notable increase, reflecting investor optimism. However, analysts remain cautious, noting that projected revenue growth is slowing. This situation presents a complex scenario for investors weighing immediate gains against long-term growth sustainability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
